Nkarta (NKTX) stock surged Monday — partially reversing a 31% dive on Friday — after unveiling promising test results for its non-Hodgkin lymphoma treatment.

The company unveiled data from five patients in a Securities and Exchange Commission filing. Its cancer treatment, dubbed NKX019, uses donor immune cells. Scientists then teach those cells to find and destroy specific problematic cells. In this case, those are CD19 cells.

After three months, the five patients no longer had any CD19 cells in their blood. Also promisingly, this type of cancer typically arises from immune cells known as B cells. These cells normalized after three months. One patients showed normal B cells after a year.

Leerink Partners analyst Daina Graybosch says the results prove the benefit for NKX019, which the company is also testing in patients with lupus nephritis. On Friday, Nkarta stock took a bath after the firm refocused its priorities to NKX019, deemphasizing an acute myeloid leukemia treatment that showed unpromising results.

On today’s stock market, Nkarta stock soared 17.6% to 10.49.

 

Nkarta Stock: Could Autoimmune Diseases Be Next?

There’s early evidence that CAR-T drugs — the class to which NKX019 belongs — could work in patients with autoimmune diseases.

“Caveats include the small sample size and indirect signal, which assumes the oncology findings translate to autoimmune diseases and these pharmacodynamics/pharmacokinetics markers correlate with clinical benefit,” Leerink’s Graybosch said in a report.

Still, she has an outperform rating on Nkarta stock.

Shares bounded back over their 50-day moving average on Monday, reversing the Friday downfall, according to MarketSurge.com. Nkarta stock has a perfect IBD Digital Relative Strength Rating of 99.

Source: https://www.investors.com/news/technology/nkarta-stock-non-hodgkin-lymphoma-lupus-nephritis/
About PackGene

PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.

Related News

Scientists develop potential stealth cancer therapy

Credit: ACS Central Science (2024). DOI: 10.1021/acscentsci.4c00559Sneaking by cancer's defenses, by disguising tumor-fighting antibodies inside the molecules cancer uses to nourish tumor growth, is the basis of a novel therapy from Yale Cancer Center researchers at...

read more

Related Services

Plasmids GMP Services

Multiple scales & grade of solutions of various kind of plasmids suitable for multiple treatments in a fast and cost effective way.
READ MORE

AAV GMP Services

Ranging from small-scale AAV production, to large-scale AAV cGMP manufacturing for animal studies.
READ MORE
aav icon

Technology Platforms

PackGene’s proprietary π-Alpha™ 293 AAV High-yield Platform increases AAV production by 3 to 8 times that of traditional platforms.
READ MORE